SOURCE: ChromoCure, Inc.

January 20, 2010 13:34 ET

ChromoCure Cites Study Published in January 15th, 2010 Issue of Cancer Research as Further Validation of Aneuploidy Theory of Cancer and Its Proprietary Detection Technology

RENO, NV--(Marketwire - January 20, 2010) - ChromoCure, Inc. (PINKSHEETS: KKUR) -- The Company announces that its long-held theory of cancer, aneuploidy, has been further validated by a study published in the January 15, 2010 issue of Cancer Research (Volume 70, Issue 2). Authors Cui, Borysova, Johnson and Guadagno, affiliated (respectively) with the Department of Molecular Oncology and Analytic Microscopy Core Facility, H. Lee Moffitt Cancer Center and Research Institute and Cancer Biology Graduate Program, University of South Florida, Tampa, Florida, concluded that "Evidence is offered for the hypothesis that the early, founding effects of B-Raf mutations on melanoma development occur initially through aneuploidy, before the benefits of activated B-Raf to transformed cell growth and survival can accrue."

These findings, together with recently announced supporting studies at the Mayo Clinic, have further validated the chromosomal theory of cancer, a theory long championed by ChromoCure. Their findings, which appear in the December 2009 issue of the journal Cancer Cell along with an independent commentary on the discovery, end a major controversy in the field of cancer research as to whether aneuploidy is a cause or a consequence of cancer and further proves the aneuploidy basis of cancer.

These ground breaking research publications have initiated renewed interest in aneuploidy research and reinforced ChromoCure's leading edge status. As recently announced, ChromoCure has accelerated the implementation of the Therapy and Cure component of ChromoCure's business plan and is reshaping other segments of its Business Plan.

The company welcomes these corroborating research publications and anticipates the announcement of important new initiatives.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems. The Company's proprietary ChromoCure CS200 Chromosomal Scanner system measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the worldwide gold standard for cancer detection, therapy and cure research.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.

Contact Information